Li Juan, Bi De, Zhang Xin, Cao Yunpeng, Lv Kun, Jiang Lan
Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Suzhou Polytechnic Institute of Agriculture, Suzhou, China.
Front Genet. 2021 Dec 20;12:799799. doi: 10.3389/fgene.2021.799799. eCollection 2021.
Glioblastoma (GBM) is the most common and aggressive primary intracranial tumor of the central nervous system, and the prognosis of GBM remains a challenge using the standard methods of treatment-TMZ, radiation, and surgical resection. Traditional Chinese medicine (TCM) is a helpful complementary and alternative medicine. However, there are relatively few studies on TCM for GBM. We aimed to find the connection between TCM and anti-GBM. Network pharmacology and inflammatory microenvironment strategy were used to predict (Luo Han Guo) target for treating glioblastoma. We mainly used network pharmacology and bioinformatics. CCL5 was significantly highly expressed in GBM with poor prognostics. Uni-cox and randomForest were used to determine that CCL5 was especially a biomarker in GBM. CCL5 was also the target for SG and TMZ. The active ingredient of Luo Han Guo - squalene and CCL5 -showed high binding efficiency. CCL5, a chemotactic ligand, was enriched and positively correlated in eosinophils. CCL5 was also the target of Luo Han Guo, and its effective active integrate compound -- squalene - might act on CCL5. SG might be a new complementary therapy of the same medicine and food, working on the target CCL5 and playing an anti-GBM effect. CCL5 might affect the immune microenvironment of GBM.
胶质母细胞瘤（GBM）是中枢神经系统最常见且侵袭性最强的原发性颅内肿瘤，使用标准治疗方法——替莫唑胺（TMZ）、放疗和手术切除，GBM的预后仍然是一个挑战。中医（TCM）是一种有益的补充和替代医学。然而，针对GBM的中医研究相对较少。我们旨在寻找中医与抗GBM之间的联系。采用网络药理学和炎症微环境策略预测罗汉果治疗胶质母细胞瘤的靶点。我们主要运用网络药理学和生物信息学。趋化因子配体5（CCL5）在预后较差的GBM中显著高表达。使用单因素Cox回归分析和随机森林算法确定CCL5尤其是GBM中的一个生物标志物。CCL5也是罗汉果甜苷（SG）和替莫唑胺的靶点。罗汉果的活性成分——角鲨烯与CCL5显示出高结合效率。CCL5作为一种趋化配体，在嗜酸性粒细胞中富集且呈正相关。CCL5也是罗汉果的靶点，其有效的活性整合化合物——角鲨烯——可能作用于CCL5。罗汉果甜苷可能是一种新的药食同源的辅助疗法，作用于靶点CCL5并发挥抗GBM作用。CCL5可能影响GBM的免疫微环境。
